Healthcare provider profile · identity verified

Rigoberto Marin, MD

Family Practice · LAWTON, OK · NPI 1487886313

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	278	82
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	223	111
Ibuprofen	Ibuprofen	196	90
Levothyroxine Sodium	Levothyroxine Sodium	173	45
Metformin Hcl	Metformin Hcl	164	47
Losartan Potassium	Losartan Potassium	150	46
Prednisone	Prednisone	137	73
Lisinopril	Lisinopril	119	35
Amlodipine Besylate	Amlodipine Besylate	111	34
Omeprazole	Omeprazole	110	39
Pantoprazole Sodium	Pantoprazole Sodium	108	31
Azithromycin	Azithromycin	100	71
Doxycycline Hyclate	Doxycycline Hyclate	100	57
Simvastatin	Simvastatin	99	23
Gabapentin	Gabapentin	95	26
Metoprolol Succinate	Metoprolol Succinate	91	34
Tamsulosin Hcl	Tamsulosin Hcl	88	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	77	23
Furosemide	Furosemide	76	28
Donepezil Hcl	Donepezil Hcl	73	12
Hydralazine Hcl	Hydralazine Hcl	72	17
Eliquis	Apixaban	70	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	70	20
Zolpidem Tartrate	Zolpidem Tartrate	66	20
Metoprolol Tartrate	Metoprolol Tartrate	63	13
Montelukast Sodium	Montelukast Sodium	61	24
Triamcinolone Acetonide	Triamcinolone Acetonide	60	27
Alendronate Sodium	Alendronate Sodium	58	16
Memantine Hcl	Memantine Hcl	58	suppressed
Levetiracetam	Levetiracetam	56	suppressed
Diclofenac Sodium	Diclofenac Sodium	54	26
Fluticasone Propionate	Fluticasone Propionate	54	27
Carvedilol	Carvedilol	53	19
Famotidine	Famotidine	48	16
Trazodone Hcl	Trazodone Hcl	48	suppressed
Glipizide	Glipizide	47	12
Meloxicam	Meloxicam	47	18
Ezetimibe	Ezetimibe	46	suppressed
Januvia	Sitagliptin Phosphate	45	suppressed
Clopidogrel	Clopidogrel Bisulfate	43	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	41	31
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	25
Benztropine Mesylate	Benztropine Mesylate	39	suppressed
Fenofibrate	Fenofibrate	37	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	37	13
Mupirocin	Mupirocin	36	20
Myrbetriq	Mirabegron	36	suppressed
Clindamycin Hcl	Clindamycin Hcl	35	21
Pregabalin	Pregabalin	35	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	35	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	suppressed
Potassium Chloride	Potassium Chloride	33	suppressed
Lurasidone Hcl	Lurasidone Hcl	32	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	32	suppressed
Ozempic	Semaglutide	32	suppressed
Tramadol Hcl	Tramadol Hcl	32	12
Albuterol Sulfate Hfa	Albuterol Sulfate	31	suppressed
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Mirtazapine	Mirtazapine	29	suppressed
Sertraline Hcl	Sertraline Hcl	29	11
Tresiba Flextouch U-100	Insulin Degludec	29	suppressed
Meropenem-0.9% Nacl	Meropenem-0.9% Sodium Chloride	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Glipizide Er	Glipizide	25	suppressed
Ketoconazole	Ketoconazole	25	16
Lactulose	Lactulose	25	12
Clonazepam	Clonazepam	24	11
Nifedipine Er	Nifedipine	23	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	23	suppressed
Baclofen	Baclofen	22	suppressed
Cephalexin	Cephalexin	21	18
Clonidine Hcl	Clonidine Hcl	21	15
Olanzapine	Olanzapine	21	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	20	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Terbinafine Hcl	Terbinafine Hcl	19	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	18	suppressed
Icosapent Ethyl	Icosapent Ethyl	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Latanoprost	Latanoprost	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Metronidazole	Metronidazole	17	13
Clobetasol Propionate	Clobetasol Propionate	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Ofloxacin	Ofloxacin	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	14
Diazepam	Diazepam	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Fluconazole	Fluconazole	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Lumigan	Bimatoprost	15	suppressed
Novolin R	Insulin Regular, Human	15	suppressed
Risperidone	Risperidone	15	suppressed
Telmisartan	Telmisartan	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Nystatin	Nystatin	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Permethrin	Permethrin	13	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	12	suppressed
Vascepa	Icosapent Ethyl	12	suppressed
Clonidine	Clonidine	11	suppressed
Finasteride	Finasteride	11	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	11	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error